Valeant Pharmaceuticals International Inc. may replace as many as five of its directors as soon as Friday, according to a person familiar with the matter, as the company overhauls its strategy and governance and plans for the arrival of its new chief executive officer.
From the 14-person board, Chairman Robert Ingram, Audit Committee Chairwoman Norma Ann Provencio, Theo Melas-Kyraizi, Ronald Farmer and Mason Morfit may all be replaced, said the person, who asked not to be identified because the matter was private.
Morfit is president of ValueAct Capital Management LLC, one of Valeant’s biggest holders.
Joe Papa, the former CEO of drugmaker Perrigo Co., is replacing outgoing CEO Mike Pearson and will also become chairman. The company announced in March that Pearson would step down after months of turmoil at the company.
Since its August peak, Valeant has lost more than 85 percent of its stock market value, failed to file its annual report, said it will restate some earnings from 2014 and 2015 and announced that it is being investigated by the U.S. Securities and Exchange Commission.
News about the board shakeup was first reported by the Wall Street Journal.
Copyright 2018 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
